Table 3. Gene set enrichment analysis.
| Pathway name | Kegg ID | Genes | P-value |
| Insulin signaling pathway | hsa04910 | 33 | 4.5E-10 |
| Colorectal cancer | hsa05210 | 21 | 7.3E-07 |
| Acute myeloid leukemia | hsa05221 | 15 | 6.7E-06 |
| Prostate cancer | hsa05215 | 20 | 1.1E-05 |
| Glioma | hsa05214 | 16 | 1.5E-05 |
| MAPK signaling pathway | hsa04010 | 41 | 1.5E-05 |
| ErbB signaling pathway | hsa04012 | 19 | 4.8E-05 |
| Chronic myeloid leukemia | hsa05220 | 17 | 8.1E-05 |
| Wnt signaling pathway | hsa04310 | 26 | 1.4E-04 |
| Melanoma | hsa05218 | 16 | 1.6E-04 |
Footnote: Fourteen of the 16 identified miRNAs were combined in a gene set enrichment analysis. miR-122* and miR-192* were not included as they were not in the applied database. The ten pathways identified with highest significance are shown.